Genzyme changes Bioenvision bid

07/2/2007 | American City Business Journals

Genzyme Corp. says many Bioenvision shareholders failed to sell their stock to the Massachusetts biotech as part of the $345 million all-cash acquisition offer. Genzyme says it is changing its tender offer so it is not required to acquire at least half of the outstanding stock, and is extending the offer to buy stock until July 10.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care